Audax Private Equity to Acquire Avantor’s Clinical Services Business
Audax Private Equity has announced a definitive agreement to acquire Avantor's Clinical Services business (NYSE: AVTR). The deal is expected to close in Q4, subject to regulatory approvals. Clinical Services provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, CROs, and diagnostic laboratories. Operating 10 facilities across the US, UK, and Europe, the business offers a global logistics and equipment services network.
The acquisition includes three primary offerings: EPL Archives, MESM, and Therapak, which provide active trial and post-trial sample storage, supply chain management, and packaging and logistics for sample collection. Audax plans to invest aggressively to expand the company's commercial and technical reach, leveraging its experience in corporate carveouts and the healthcare sector.
Audax Private Equity ha annunciato un accordo definitivo per acquisire il business dei Servizi Clinici di Avantor (NYSE: AVTR). Si prevede che l'affare si concluda nel quarto trimestre, soggetto all'approvazione degli organi di regolamentazione. I Servizi Clinici forniscono servizi di trial clinico e di supply chain di laboratorio a aziende farmaceutiche e biotecnologiche, CRO e laboratori diagnostici. Operando in 10 strutture negli Stati Uniti, nel Regno Unito e in Europa, l'azienda offre una rete globale di logistica e servizi per attrezzature.
L'acquisizione include tre offerte principali: EPL Archives, MESM e Therapak, che offrono stoccaggio attivo di campioni durante e dopo gli studi, gestione della supply chain, e imballaggio e logistica per la raccolta di campioni. Audax prevede di investire in modo aggressivo per espandere la portata commerciale e tecnica dell'azienda, sfruttando la sua esperienza in carveout aziendali e nel settore sanitario.
Audax Private Equity ha anunciado un acuerdo definitivo para adquirir el negocio de Servicios Clínicos de Avantor (NYSE: AVTR). Se espera que el acuerdo se cierre en el cuarto trimestre, sujeto a aprobaciones regulatorias. Los Servicios Clínicos proporcionan servicios de ensayos clínicos y gestión de la cadena de suministro de laboratorio a empresas farmacéuticas y biotecnológicas, CROs y laboratorios de diagnóstico. Con 10 instalaciones en EE. UU., Reino Unido y Europa, el negocio ofrece una red global de logística y servicios de equipos.
La adquisición incluye tres ofertas principales: EPL Archives, MESM y Therapak, que ofrecen almacenamiento activo de muestras durante y después del ensayo, gestión de la cadena de suministro, así como empaque y logística para la recolección de muestras. Audax planea invertir agresivamente para expandir el alcance comercial y técnico de la empresa, aprovechando su experiencia en carveouts corporativos y en el sector de la salud.
Audax Private Equity는 Avantor의 임상 서비스 사업부(NYSE: AVTR)를 인수하기로 최종 계약을 체결했다고 발표했습니다. 거래는 규제 승인을 조건으로 4분기에 완료될 것으로 예상됩니다. 임상 서비스는 제약 및 생명공학 회사, CRO, 진단 실험실에 임상 시험 및 실험실 공급망 서비스를 제공합니다. 미국, 영국, 유럽에 10개의 시설을 운영하며, 글로벌 물류 및 장비 서비스 네트워크를 제공합니다.
이번 인수에는 EPL Archives, MESM, Therapak의 세 가지 주요 제공 서비스가 포함되어 있으며, 이는 임상 시험 및 시험 후 샘플 저장, 공급망 관리, 샘플 수집을 위한 포장 및 물류를 제공합니다. Audax는 기업 분할 및 의료 분야에서의 경험을 활용하여 회사의 상업적 및 기술적 범위를 확장하기 위해 공격적으로 투자할 계획입니다.
Audax Private Equity a annoncé un accord définitif pour acquérir le secteur des services cliniques d'Avantor (NYSE: AVTR). Ce contrat doit être finalisé au quatrième trimestre, sous réserve des approbations réglementaires. Les services cliniques fournissent des services d'essais cliniques et de chaîne d'approvisionnement pour les laboratoires aux entreprises pharmaceutiques et biotechnologiques, aux CRO et aux laboratoires de diagnostic. Avec 10 installations aux États-Unis, au Royaume-Uni et en Europe, l'entreprise propose un réseau mondial de logistique et de services d'équipement.
L'acquisition comprend trois offres principales : EPL Archives, MESM et Therapak, qui fournissent le stockage actif d'échantillons pendant et après les essais, la gestion de la chaîne d'approvisionnement ainsi que l'emballage et la logistique pour la collecte d'échantillons. Audax prévoit d'investir de manière agressive pour étendre la portée commerciale et technique de l'entreprise, en tirant parti de son expérience dans les cessions d'entreprises et le secteur de la santé.
Audax Private Equity hat eine endgültige Vereinbarung zur Übernahme des Geschäftsbereichs Klinische Dienste von Avantor (NYSE: AVTR) angekündigt. Der Vertrag soll im vierten Quartal abgeschlossen werden, vorbehaltlich der Genehmigung durch die Aufsichtsbehörden. Klinische Dienste bieten Dienstleistungen für klinische Studien und die Lieferkette im Labor für Unternehmen der Pharma- und Biotechnologie, CROs und diagnostische Labore an. Mit 10 Standorten in den USA, dem Vereinigten Königreich und Europa betreibt das Unternehmen ein globales Netzwerk für Logistik und Geräte.
Die Übernahme umfasst drei Hauptangebote: EPL Archives, MESM und Therapak, die aktives Probenlagerung während und nach klinischen Studien, Lieferkettenmanagement sowie Verpackungs- und Logistikdienstleistungen für die Probenentnahme bereitstellen. Audax plant, aggressiv zu investieren, um die kommerziellen und technischen Kapazitäten des Unternehmens zu erweitern und dabei auf seine Erfahrung in Unternehmensverkäufen und im Gesundheitssektor zurückzugreifen.
- Acquisition of Avantor's Clinical Services business by Audax Private Equity
- Expansion of Audax's portfolio in the healthcare and pharma services sector
- Potential for aggressive investment and expansion of Clinical Services' capabilities
- Acquisition includes valuable brands: EPL Archives, MESM, and Therapak
- Avantor divesting its Clinical Services business, potentially impacting its revenue stream
- Deal subject to regulatory approvals, which could delay or complicate the acquisition
Audax Private Equity's acquisition of Avantor's Clinical Services business is a strategic move in the healthcare sector. This deal highlights the growing importance of clinical trial support services in the pharmaceutical industry. For Avantor (NYSE: AVTR), this divestiture could potentially streamline operations and free up capital for core business focus. However, it also means losing a revenue stream from a growing sector. The impact on Avantor's stock may depend on how effectively they reinvest the proceeds. For investors, it's important to monitor Avantor's post-sale performance and Audax's plans to grow the acquired business.
This acquisition underscores the increasing demand for specialized clinical trial services. The Clinical Services business, with its global reach and comprehensive offerings, is well-positioned in a high-growth market. Audax's commitment to invest aggressively suggests potential for expansion and innovation in clinical trial support. This could lead to improved efficiency in drug development processes, potentially benefiting the entire pharmaceutical industry. Investors should watch for how this acquisition might reshape the competitive landscape in clinical trial services and its ripple effects on CROs and pharma companies.
The clinical trial services market is experiencing robust growth, driven by increasing R&D spending in pharmaceuticals and the complexity of trials. This acquisition positions Audax to capitalize on this trend. The deal's structure as a corporate carve-out is noteworthy, as it allows for focused investment and potential value creation. Audax's track record in healthcare and experience with carve-outs could be a positive indicator for the business's future performance. For investors, this deal highlights the attractiveness of specialized healthcare services and may signal further consolidation in the sector.
Clinical Services provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, contract research organizations (CROs), and diagnostic laboratories. The business operates 10 facilities across the US,
“We appreciate the unique capabilities that this business delivers to some of the most demanding customers in the pharma and life sciences sectors, and we look forward to investing aggressively to expand the Company’s commercial and technical reach,” said David Wong, Partner at Audax Private Equity. “We believe the services that this business provides represent the backbone for advancing therapeutic development.”
The Company provides active trial and post-trial sample storage and archiving, supply chain management, and packaging and logistics for sample collection through three primary offerings and well-respected brand names: EPL Archives, MESM, and Therapak.
Audax has completed several corporate carveouts in the past, including the acquisitions of Aspen Surgical, Lifemark, and others. The firm also brings deep experience in the healthcare space, with a portfolio that includes companies in pharma services, life science tools, medical technology, and value-based care.
“We're pleased to work with Avantor to effect a quick and seamless transition to the benefit of all of our stakeholders,” added Stephen Weaver, Managing Director at Audax Private Equity. "The investments we intend to make to this platform should deliver tremendous benefit to our clients and our team members."
Audax is investing through its flagship fund.
Moelis & Company LLC served as financial advisor and Ropes & Gray LLP served as legal counsel to Audax Private Equity. J.P. Morgan Securities LLC served as financial advisor to Avantor and Arnold & Porter served as Avantor’s legal advisor.
ABOUT AUDAX PRIVATE EQUITY
Headquartered in
ABOUT AVANTOR
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240816164268/en/
Audax Private Equity Media Contacts
Zachary Tramonti / Catherine Livingston
FGS Global
Audax@fgsglobal.com
Source: Audax Private Equity
FAQ
What is Audax Private Equity acquiring from Avantor (AVTR)?
When is the acquisition of Avantor's (AVTR) Clinical Services expected to close?
What services does Avantor's (AVTR) Clinical Services business offer?
How many facilities does Avantor's (AVTR) Clinical Services business operate?
